CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies
Use este enlace para citar
http://hdl.handle.net/2183/28555
A non ser que se indique outra cousa, a licenza do ítem descríbese como Atribución 4.0 Internacional
Coleccións
- II - Artigos [434]
Metadatos
Mostrar o rexistro completo do ítemTítulo
CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical StudiesAutor(es)
Data
2021-06-22Cita bibliográfica
González de Aledo, M.; González-Bardanca, M.; Blasco, L.; Pacios, O.; Bleriot, I.; Fernández-García, L.; Fernández-Quejo, M.; López, M.; Bou, G.; Tomás, M. CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies. Antibiotics 2021, 10, 756. https://doi.org/10.3390/antibiotics10070756
Resumo
[Abstract] One of the biggest threats we face globally is the emergence of antimicrobial-resistant (AMR) bacteria, which runs in parallel with the lack in the development of new antimicrobials. Among these AMR bacteria pathogens belonging to the ESKAPE group can be highlighted (Enterococcus spp., Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.) due to their profile of drug resistance and virulence. Therefore, innovative lines of treatment must be developed for these bacteria. In this review, we summarize the different strategies for the treatment and study of molecular mechanisms of AMR in the ESKAPE pathogens based on the clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins’ technologies: loss of plasmid or cellular viability, random mutation or gene deletion as well directed mutations that lead to a gene’s loss of function.
Palabras chave
CRISPR-Cas
ESKAPE pathogens
Treatment
ESKAPE pathogens
Treatment
Descrición
This article belongs to the Special Issue Non-antimicrobial Agents as Adjuvants against Bacterial Infections
Versión do editor
Dereitos
Atribución 4.0 Internacional
ISSN
2079-6382